Preprint Review Version 1 This version is not peer-reviewed

Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review

Version 1 : Received: 16 March 2020 / Approved: 17 March 2020 / Online: 17 March 2020 (09:17:53 CET)

How to cite: Kearney, J. Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review. Preprints 2020, 2020030275 (doi: 10.20944/preprints202003.0275.v1). Kearney, J. Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review. Preprints 2020, 2020030275 (doi: 10.20944/preprints202003.0275.v1).

Abstract

There is a long trail of research studies testing the in vitro and in vivo efficacy of chloroquine and its derivatives in treating and preventing infection by various coronavirus species. More recent findings have highlighted the possibility of treating patients infected with the 2019 novel coronavirus, SARS-CoV-2. This review describes the mechanism of coronavirus infection, the mechanism of action of chloroquine, and summarizes the available literature highlighting the efficacy of chloroquine as an anti-coronavirus agent. These findings should encourage the wider scientific community to conduct thorough research on the possible efficacy of chloroquine and its derivatives in treating and preventing SARS-CoV-2 infection.

Subject Areas

Antimalarial; Chemoprophylaxis; Chloroquine; Coronavirus; COVID-19; Global Health; Hydroxychloroquine; Public Health; SARS-CoV-2; Virus

Comments (3)

Comment 1
Received: 19 March 2020
Commenter: John
The commenter has declared there is no conflict of interests.
Comment: 03/17 - Submitted for peer-review at the International Journal of Molecular Sciences.
+ Respond to this comment
Comment 2
Received: 2 April 2020
Commenter: John Kearney
The commenter has declared there is no conflict of interests.
Comment: Several trials are beginning in the United States testing the post-exposure prophylaxis use of hydroxychloroquine. One trial at the University of Minnesota (https://med.umn.edu/news-events/covid-19-clinical-trial-launches-university-minnesota) and another at the University of Washington (https://newsroom.uw.edu/news/does-antimalarial-drug-prevent-covid-19-study-seeks-answers.
+ Respond to this comment
Comment 3
Received: 22 April 2020
Commenter: John Kearney
The commenter has declared there is no conflict of interests.
Comment: Preprint of US study of HCQ use in infected individuals in VA hospital system has shown no benefit in those taking HCQ versus a control. https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v1
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 3
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.